NL-OMON37576已完成不适用
A SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, FOUR-WAY-CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETIC PROFILE OF THE HP-5000 PATCH (DICLOFENAC SODIUM TRANSDERMAL DRUG DELIVERY SYSTEM) FOLLOWING 24-HOUR APPLICATION COMPARED TO FLECTOR® AND VOLTAREN® 100 MG IN HEALTHY ADULT MALE AND FEMALE SUBJECTS UNDER FASTING CONDITIONS - HP-5000 transdermal patch study
oven Pharmaceuticals, Inc.0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male and female subjects
- •18-40 yrs, inclusive
- •BMI: 18.0-30.0 kg/m2, inclusive
- •non-smoking
- •light skin color
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 4-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETIC PROFILE OF FLURBIPROFEN FOLLOWING ADMINISTRATION OF 2 FLURBIPROFEN TRANSDERMAL FORMULATIONS COMPARED TO FROBEN® 50 MG AND YAKUBAN TAPE® IN HEALTHY SUBJECTSontstekingenInflammationNL-OMON38802PRA International EDS18
尚未招募
1 期
An Open Label, Single-Center, Single Dose Combination of HSK3486 and Etomidate Intravenous Bolus Injection to Determine the Safety, Pharmacodynamics and Pharmacokinetics for Induction of Anesthesia in Healthy Male SubjectsAnesthesiaAnaesthesiology - AnaestheticsACTRN12616001620415Sichuan Haisco Pharmaceutical Co., Ltd25
已完成
不适用
A SINGLE DOSE, RANDOMIZED, OPEN-LABEL, 4-WAY CROSSOVER STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ESKETAMINE (ORAL TABLET OF 20 MG AND 100 MG, ORAL SOLUTION OF 20 MG AND IV INFUSION OF 20 MG) IN HEALTHY VOLUNTEERS.Depression.10027946NL-OMON43097CIMA Labs, Inc16
已完成
不适用
A SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, THREE-WAY-CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF THE HP-3070 PATCH (ASENAPINE TRANSDERMAL DRUG DELIVERY SYSTEM) FOLLOWING 24-HOUR APPLICATION COMPARED TO SINGLE-DOSE SYCREST® 5 MG (ASENAPINE, SUBLINGUAL) IN HEALTHY ADULT MALE AND FEMALE SUBJECTSbipolar disorder10026753SchizophreniaNL-OMON36902oven Pharmaceuticals, Inc.18
进行中（未招募）
1 期
Open label, non-randomized, single dose PK/PD study in adolescent asthmatic patients and adult asthmatic patientsasthmaEUCTR2019-002238-35-PLChiesi Farmaceutici S.p.A.80